Corporate Profile

Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, GRN1005 and imetelstat. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel, across the blood-brain barrier (BBB) by targeting low-density lipoprotein receptor-related proteins (LRPs) that are expressed on the BBB. GRN1005 is being evaluated in two Phase 2 clinical trials: brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. Imetelstat is a telomerase inhibitor that is being evaluated in Phase 2 clinical trials for hematologic malignancies.

Stock Performance

GERN (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	**$1.15**
Change (%)	0.00 (0.00%)
Volume	1,026,125
52 Week Low	$0.91
Market Cap	$149,994,500
Rolling EPS	-0.48
PE Ratio	N/A
Shares Outstanding	130,430,000

Data as of 06/18/13 4:00 p.m. ET

Recent Headlines & Events

06/16/13
Updated Results from Geron's Imetelstat Phase 2 Proof-of-Concept Trial in Essential Thrombocythemia Presented at the European Hematology Association Congress

05/28/13
Geron to Present at the Jefferies Global Healthcare Conference

04/25/13
Geron Updates Imetelstat Development Strategy, Including Progress of Investigator-Sponsored Study in Myelofibrosis

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 3.4



EPS Trend				
		Current	30 Days Ago	90 Days Ago
QTR	Jun 13	-0.07	-0.07	-0.06
QTR	Sep 13	-0.07	-0.07	-0.06
QTR	Dec 13	-0.07	-0.07	-0.06
QTR	Mar 14	-0.09	-0.09	-0.08
FY	Dec 13	-0.30	-0.30	-0.27
FY	Dec 14	-0.32	-0.32	-0.30

SEC Filings

Filing Date	Form
05/24/13	4
05/24/13	4
05/24/13	4
05/24/13	4

Powered By EDGAR Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed